Modeling & Simulations:
essential for every clinical development
Since the 2000s, disruptive changes in the pharma industry and the emergence of applied M&S techniques have markedly transformed R&D organization. More than ever, we remain a preferred and reliable partner for Biotech companies to bring appropriate use of Pharmacometrics and Modeling to their drug development.
A strategy built around 3 complementary axes
Today, PhinC Development is a key European partner for the integration of modeling & simulation approaches across the entire drug development lifecycle. Our strength is built on three core pillars that secure critical decisions and accelerate execution.
Deep learning & advanced modeling
We develop the best models to make the most of the research data at every phase (in vitro, in vivo animal and human) and to carry out robust simulations and predictions that are requested by health agencies.
Tailor-made support & advice
PhinC supports its partners from the first phases and brings its experience, informed recommendations and a Modeling strategy adapted to each development program.
Agility & Biotech orientation
PhinC adapts its work organization to meet the specificities of Biotechs (funding method, attrition rate, stakeholders interaction, advice upstream on the development strategy, etc.).
Predictive models to overcome the
main challenges of your development
Faced with some major obstacles and challenges, PhinC brings its expertise in pharmacometry, pharmacokinetics, pharmacology and biostatistics to develop innovative predictive models. Such models are now extremely powerful tools, able to give Biotechs a decisive advantage in the race to develop drug candidates. Indeed, they make it possible to handle a multitude of «challenges»
01
the increasing complexity of test
protocols
02
the multiplication of data sources
03
Risk management
04
ethical requirements and cost reduction
05
the need for « derisking »
Our goal
In practice, our approaches help optimize study designs, reduce unnecessary iterations, and secure critical decisions (dose, regimen, therapeutic windows, interactions, variability).